Compare Natera Inc. Common Stock (NTRA) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Quantum Computing Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Quantum Computing Inc trades at $6.19 (market cap $1.43B). The key difference: Natera Inc. Common Stock is far larger — about 39.9× Quantum Computing Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Quantum Computing Inc for 26 Days on average.
| NTRA | QUBT | |
|---|---|---|
Market Cap | $57.03B | $1.43B |
Volume | 1,131,157 | 8,329,766 |
Sector | Health | Technology |
52-Week High | $425.64 | $21.23 |
52-Week Low | $179.42 | $6.31 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $56.18B | $495.20M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Quantum Computing Inc. (QUBT) trades at $6.87, down 0.87% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and cash burn persist.
While analyst consensus is bullish with a $17.33 price target (75% buy ratings), QUBT faces significant execution risks as it scales quantum hardware production. The stock offers substantial upside potential if commercialization succeeds but carries high volatility given pre-profitability status and competitive quantum computing landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
